Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy.
Hyperphenylalaninemia in infants and children may be caused by a deficiency of dihydropteridine reductase (DHPR). Recommended therapy includes folinic acid as a source of tetrahydrofolate, a phenylalanine-restricted diet, and both dopamine and serotonin precursors. We report a child with progressive basal ganglia and other subcortical calcifications prior to the use of folinic acid. Six other reported cases of DHPR deficiency demonstrated similar calcifications prior to folinic acid therapy. Since this pattern of calcification also resembles that seen in CNS folate deficiency caused by both congenital folate deficiency and that which is methotrexate-induced, we propose that intracranial calcification in DHPR deficiency is caused by inadequate CNS tetrahydrofolate and may be prevented by the use of folinic acid. Our patient achieved excellent seizure control following the use of folinic acid, suggesting either a direct or indirect anticonvulsant effect of this compound in patients with DHPR deficiency.
Woody
R C
RC
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.
Brewster
M A
MA
Glasier
C
C
D001921:Brain / Q000000981:diagnostic imaging; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000209:etiology*; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000209:etiology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D002955:Leucovorin / Q000627:therapeutic use*; D009247:NADH, NADPH Oxidoreductases / Q000172:deficiency*; D010661:Phenylketonurias; D012640:Seizures / Q000209:etiology; D014057:Tomography, X-Ray Computed
D009247:NADH, NADPH Oxidoreductases; D002955:Leucovorin